DNA甲基化
生物
CD19
CD8型
癌症研究
祖细胞
免疫学
分子生物学
细胞生物学
干细胞
遗传学
基因
免疫系统
基因表达
作者
Caitlin C. Zebley,Charmaine Brown,Mi Tian,Yiping Fan,Shanta Alli,Shannon K. Boi,G Galletti,Enrico Lugli,Deanna Langfitt,Jean‐Yves Métais,Timothy Lockey,Michael M. Meagher,Brandon M. Triplett,Aimee C. Talleur,Stephen Gottschalk,Ben Youngblood
出处
期刊:Cell Reports
[Cell Press]
日期:2021-11-01
卷期号:37 (9): 110079-110079
被引量:42
标识
DOI:10.1016/j.celrep.2021.110079
摘要
CD19-CAR T cell therapy has evolved into the standard of care for relapsed/refractory B cell acute lymphoblastic leukemia (ALL); however, limited persistence of the CAR T cells enables tumor relapse for many patients. To gain a deeper understanding of the molecular characteristics associated with CAR T cell differentiation, we performed longitudinal genome-wide DNA methylation profiling of CD8+ CD19-CAR T cells post-infusion in ALL patients. We report that CAR T cells undergo a rapid and broad erasure of repressive DNA methylation reprograms at effector-associated genes. The CAR T cell post-infusion changes are further characterized by repression of genes (e.g., TCF7 and LEF1) associated with memory potential and a DNA methylation signature (e.g., demethylation at CX3CR1, BATF, and TOX) demarcating a transition toward exhaustion-progenitor T cells. Thus, CD19-CAR T cells undergo exhaustion-associated DNA methylation programming, indicating that efforts to prevent this process may be an attractive approach to improve CAR T cell efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI